Valuation: Celldex Therapeutics, Inc.

Market Cap 327.55Cr 283.76Cr 265.34Cr 242.49Cr 456.53Cr 31TCr 464.25Cr 3.11TCr 1.22TCr 16TCr 1.23TCr 1.2TCr 52TCr P/E 2026 *
-10.2x
P/E 2027 * -10.3x
Enterprise Value 268.63Cr 232.72Cr 217.61Cr 198.87Cr 374.41Cr 26TCr 380.74Cr 2.55TCr 999.92Cr 13TCr 1.01TCr 986.64Cr 43TCr EV / Sales 2026 *
1,920x
EV / Sales 2027 * 262x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

1 day+3.02%
1 week+12.90%
Current month+12.90%
1 month+10.24%
3 months+26.49%
6 months+73.20%
Current year+58.21%
1 week 37.54
Extreme 37.54
43.21
1 month 33.37
Extreme 33.37
43.21
Current year 22.33
Extreme 22.33
43.21
1 year 19.72
Extreme 19.7225
43.21
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap.
25/06/26 Free

Executive/Senior Manager

20,000 0.0255%
25/06/26 Free

Director

26,000 0.0331%
25/06/26 Free

Chief Technology Officer

57,000 0.0726%
Change 5-day change 1-year change 3-year change Capi.($)
+3.02%+12.90%+107.99%+40.79% 327.55Cr
+1.29%+3.09%+6.43%+18.53% 4.95TCr
+0.89%+10.37%+491.34%+598.75% 4.4TCr
+3.08%+13.60%+24.57%+78.98% 3.96TCr
+1.38%+2.97%+34.54%+10.66% 3.93TCr
+0.85%+7.66%+21.22%+48.78% 3.24TCr
+0.08%+4.80% - - 1.68TCr
+1.99%+4.39%+38.70%+126.93% 1.65TCr
+0.34%+2.76%+5.39%+20.43% 1.4TCr
+3.56%+19.13%+86.23%+28.36% 1.28TCr
Average +1.65%+7.59%+90.71%+108.02% 2.68TCr
Weighted average by Cap. +1.50%+7.10%+107.88%+140.26%

Financials

2026 *2027 *
Net sales 13.99L 12.12L 11.33L 10.36L 19.5L 13Cr 19.83L 1.33Cr 52.08L 6.67Cr 52.52L 51.39L 22Cr 1Cr 86.9L 81.26L 74.26L 1.4Cr 96Cr 1.42Cr 9.51Cr 3.73Cr 48Cr 3.77Cr 3.68Cr 159.73Cr
Net income -32Cr -28Cr -26Cr -24Cr -45Cr -3.05TCr -45Cr -303.53Cr -119.17Cr -1.53TCr -120.17Cr -117.59Cr -5.1TCr -36Cr -31Cr -29Cr -26Cr -50Cr -3.39TCr -50Cr -337.21Cr -132.39Cr -1.7TCr -133.51Cr -130.63Cr -5.66TCr
Net Debt -59Cr -51Cr -48Cr -44Cr -82Cr -5.61TCr -84Cr -558.62Cr -219.32Cr -2.81TCr -221.16Cr -216.41Cr -9.38TCr -65Cr -56Cr -53Cr -48Cr -91Cr -6.19TCr -92Cr -616.24Cr -241.94Cr -3.1TCr -243.97Cr -238.73Cr -10TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
10/26/10 $42.97 +3.02% 7,27,554
07/26/07 $41.71 +0.36% 8,08,912
06/26/06 $41.56 +1.22% 7,99,089
05/26/05 $41.06 +5.15% 7,88,876
04/26/04 $39.05 +3.61% 10,27,484
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
42.97USD
Average target price
58.07USD
Spread / Average Target
+35.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock